|
市場調查報告書
C型肝炎的標靶治療
Competitor Analysis: Targeted Therapy of Hepatitis C
|
C型肝炎的標靶治療 是由出版商La Merie Publishing在2011年08月所出版的。
這份英文市場調查報告書包含91 Pages 價格從美金826起跳。
本報告提供C型肝炎的抗病毒治療相關分析，新分子靶標研究開發現況與各企業開發平台相關彙整，為您概述為以下內容。
C型肝炎的標靶治療
- HCV(C型肝炎病毒)蛋白酶抑制劑
- HCV RNA聚合酶抑制劑
- 親環蛋白抑制劑
- HCV NS5A蛋白質抑制劑
- HCV NS4B-RNA結合抑制劑
- HCV治療用·預防用疫苗
- HCV治療用抗體
- HCV病毒侵入抑制劑
- HCV複製抑制劑
- 新的作用機制:病毒及宿主細胞
- TLR受體激動劑
- C型肝炎研究開發平台為目標的各種企業
- 關於 La Marie
C型肝炎標靶治療的研究開發平台的推動企業
- Abbott
- Achillion Pharmaceuticals
- Alios Biopharma
- Altor Biosciences
- Anadys Pharmaceuticals
- Astexa Therapeutics
- Avila Therapeutics
- Bionor Immuno
- Biotica Technology
- Biotron
- Boehringer Ingelheim
- Bristol-Myers Squibb
- C-Pharma
- Can-Fite BioPharma
- Chimerix
- ChronTech Pharma
- Compass Biotechnologies
- Conatus Pharmaceuticals
- CureTech
- Cytheris
- Debiopharma
- Dynavax Technologies
- Eiger Pharmaceuticals
- Enanta Pharmaceuticals
- Epiphany Biosciences
- Epixis
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- GlobeImmune
- Heat Biologics
- Idenix Pharmaceuticals
- Idera Pharmaceuticals
- Inhibitex
- Inovio
- Intellektualniy Dialog
- Intercell
- iTherX Pharmaceuticals
- 日本煙草公司
- Johnson & Johnson
- Medivir
- Massachusetts Biologic Laboratories
- Merck & Co.
- 三菱田邊製藥
- Morningside Asia Benture
- Novartis
- Okairos
- 小野藥品工業
- Padadin Biosciences
- Peregrine Pharmaceuticals
- Pfizer
- Pharmasset
- Presidio Pharmaceuticals
- Progenics Pharmaceuticals
- Regulus Therapeutics
- Replicor
- Roche
- Rosetta Genomix
- Samaritan Pharmaceuticals
- Santaris Pharma
- SCYNEXIS
- Tacere Therapeutics
- TaiGen Biotechnology
- Teva Pharmaceutical Industries
- Theravance
- Transgene
- Tripep
- Vertex Pharmaceuticals
- Viriome
- Virionics
- ViroBay
Abstract
Description
The present Competitive Intelligence Report about Targeted Therapy of
Hepatitis C provides a competitor evaluation in the field of specifically
targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011.
Purchase of the downloadable pdf report includes a 6-month online access to
the data of the report and any updates since the publication date. Credentials
to access the database will be sent by e-mail and allow online work with the
project data to print or export an individual report.
Most hepatitis C virus (HCV) infected individuals seeking treatment are
chronically infected. Treatment goal is to achieve a sustained virological
response (SVR), which is the absence of serum HCV RNA up to 6 months after
therapy is concluded. To increase efficiency of interferon treatment,
pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with
ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted
in a further increase in treatment efficiency with 54% of HCV infected
patients achieving SVR. The response and rate of SVR is dependent on the
genotype of HCV with only 30% of genotype 1 infected individuals achieving
SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination
therapy. Combination therapy treatment regiments are genotype dependent and
the amount of peg-IFN-α administered is dependent on the type used.
The suboptimal response has led to a shift in the investigational focus for
treatment of HCV toward specifically targeted antiviral therapy for HCV
agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with
frequent side effects and have a negative impact on the patient' s quality of
life.
The report includes a compilation of current active projects in research and
development of molecules specifically directed against novel targets in
hepatitis C. In addition, the report lists company-specific R&D pipelines of
targeted therapeutics in hepatitis C. Competitor projects are listed in a
tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- HCV Protease Inhibitors
- HCV RNA Polymerase Inhibitors
- Cyclophilin Inhibitors
- HCV NS5A Protein Inhibitors
- HCV NS4B-RNA Binding Inhibitors
- Therapeutic & Preventative HCV Vaccines
- Therapeutic HCV Antibodies
- HCV Viral Entry Inhibitors
- HCV Replication Inhibitors
- Novel Mechanism of Action HCV Virus & Host Cell Targets
- TLR Agonists
- Various
- Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
- About La Merie
Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
- Abbott
- Achillion Pharmaceuticals
- Alios Biopharma
- Altor Biosciences
- Anadys Pharmaceuticals
- Astex Therapeutics
- Avila Therapeutics
- Bionor Immuno
- Biotica Technology
- Biotron
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- C-Pharma
- Can-Fite BioPharma
- Chimerix
- ChronTech Pharma
- Compass Biotechnologies
- Conatus Pharmaceuticals
- CureTech
- Cytheris
- Debiopharm
- Dynavax Technologies
- Eiger Pharmaceuticals
- Enanta Pharmaceuticals
- Epiphany Biosciences
- Epixis
- Genmab
- GenPhar
- Gilead Sciences
- GlaxoSmithKline (GSK)
- GlobeImmune
- Heat Biologics
- Idenix Pharmaceuticals
- Idera Pharmaceuticals
- Inhibitex
- Inovio
- Intellektualniy Dialog
- Intercell
- iTherX Pharmaceuticals
- Japan Tobacco
- Johnson & Johnson (J&J)
- Medivir
- Massachusetts Biologic Laboratories (MBL)
- Merck & Co
- Mitsubishi Tanabe Pharma
- Morningside Asia Venture
- Novartis
- Okairos
- Ono Pharmaceutical
- Paladin Biosciences
- Peregrine Pharmaceuticals
- Pfizer
- Pharmasset
- PTC Therapeutics
- Presidio Pharmaceuticals
- Progenics Pharmaceuticals
- Regulus Therapeutics
- Replicor
- Roche
- Rosetta Genomics
- Samaritan Pharmaceuticals
- Santaris Pharma
- SCYNEXIS
- Tacere Therapeutics
- TaiGen Biotechnology
- Teva Pharmaceutical Industries
- Theravance
- Transgene
- Tripep
- Vertex Pharmaceuticals
- Viriome
- Virionics
- ViroBay
Table of Contents
1. Targeted Therapy of Hepatitis C
- HCV Protease Inhibitors
- HCV RNA Polymerase Inhibitors
- Cyclophilin Inhibitors
- HCV NS5A Protein Inhibitors
- HCV NS4B-RNA Binding Inhibitors
- Therapeutic & Preventative HCV Vaccines
- Therapeutic HCV Antibodies
- HCV Viral Entry Inhibitors
- HCV Replication Inhibitors
- Novel Mechanism of Action HCV Virus & Host Cell Targets
- TLR Agonists
- Various
2. Corporate Targeted Therapy of Hepatitis C R&D
- Pipelines
- Abbott
- Achillion Pharmaceuticals
- Alios Biopharma
- Altor Biosciences
- Anadys Pharmaceuticals
- Astex Therapeutics
Competitor Analysis
- Avila Therapeutics
- Bionor Immuno
- Biotica Technology
- Biotron
- Boehringer Ingelheim
- Bristol-Myers Squibb (BMS)
- C-Pharma
- Can-Fite BioPharma
- Chimerix
- ChronTech Pharma
- Compass Biotechnologies
- Conatus Pharmaceuticals
- CureTech
- Cytheris
- Debiopharm
- Dynavax Technologies
- Eiger Pharmaceuticals
- Enanta Pharmaceuticals
- Epiphany Biosciences
- Epixis
- Genmab
- GenPhar
- Gilead Sciences
- GlaxoSmithKline (GSK)
- GlobeImmune
- Heat Biologics
- Idenix Pharmaceuticals
- Idera Pharmaceuticals
- Inhibitex
- Inovio
- Intellektualniy Dialog
- Intercell
- iTherX Pharmaceuticals
- Japan Tobacco
- Johnson & Johnson (J&J)
- Medivir
- Massachusetts Biologic Laboratories (MBL)
- Merck & Co
- Mitsubishi Tanabe Pharma
- Morningside Asia Venture
- Novartis
- Okairos
- Ono Pharmaceutical
- Paladin Biosciences
- Peregrine Pharmaceuticals
- Pfizer
- Pharmasset
- PTC Therapeutics
- Presidio Pharmaceuticals
- Progenics Pharmaceuticals
- Regulus Therapeutics
- Replicor
- Roche
- Rosetta Genomics
- Samaritan Pharmaceuticals
- Santaris Pharma
- SCYNEXIS
- Tacere Therapeutics
- TaiGen Biotechnology
- Teva Pharmaceutical Industries
- Theravance
- Transgene
- Tripep
- Vertex Pharmaceuticals
- Viriome
- Virionics
- ViroBay
|
